Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
30–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Are outpatients, male or female, 30 through 75 years of age
Meet diagnostic criteria for major depression episode and a clinical diagnosis of idiopathic Parkinson's disease
Have a clinician-rated 17-item Hamilton Depression Rating Scale (HAMD17) total score greater than or equal to 15, a Beck Depression Inventory (BDI) total score greater than or equal to 13 and a Clinical Global Impression of Severity (CGI-S) score greater than or equal to 3 at both Visit 1 and Visit 2
Have satisfactory cognitive function
Have been held on stable dosage of antiparkinsonian medications for at least 4 weeks immediately prior to Visit 1
You may not be if
Any current primary psychiatric diagnosis other than Major depressive episode, and any personality disorder that could interfere with the compliance with the study protocol
Atypical or secondary parkinsonism due to drugs or diseases with features of Parkinson's disease
Motor conditions for which it is to be expected to change the antiparkinsonian treatment during the course of the study
Clinically significant laboratory abnormalities or serious, unstable medical illness
Lack of response of current episode to two or more adequate courses of antidepressant therapy
Clareo Health | Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
